JD.com (JD) is down sharply Monday morning, so let's check on the charts. In our last review of JD back on March 11 we wrote that "JD was trading higher on a Q4 earnings beat, according to media reports. The $85-$80 area seems to be pretty good support but the bearish divergence from the weekly OBV line tells me to not rush to be a buyer."
More from Investing
AdvisorShares Psychedelics ETF, which is adding Mindset Pharma and lists Cybin as a top holding, looks like a good trip.
Today's digital tools enable individual investors to quickly and easily acquire as much knowledge as large institutions.
Let's pay a visit to the charts of the U.S.-based steelmaker.